Pharmacological Management of Atrial Fibrillation After Cardiac Surgery

New-onset atrial fibrillation remains the most common arrhythmia encountered following cardiac surgery, with reported incidence between 20 and 40 percent depending on patient profile, operative approach, and surveillance intensity. The rhythm disturbance typically emerges within the first 72 hours, frequently triggered by pericardial inflammation, electrolyte shifts, sympathetic surge, and the haemodynamic strain of coming off cardiopulmonary bypass. For the treating clinician, the situation demands rapid decisions about rate versus rhythm control, the selection of agents that do not impair ventricular performance, and the safe introduction of antithrombotic therapy once haemostasis is secure. Drug choice is rarely straightforward because patients are already receiving analgesics, inotropes, and prophylactic antibiotics that interact with antiarrhythmic agents.

The Australian context adds specific nuances. Cardiac surgical units based in tertiary centres such as Royal Melbourne Hospital, the Royal Prince Alfred Hospital in Sydney, Monash Medical Centre, and the Prince Charles Hospital in Brisbane manage thousands of valve, coronary, and aortic procedures each year, generating well-characterised local datasets through initiatives like ANZACS-QI. Local prescribing culture is shaped by the Pharmaceutical Benefits Scheme, which subsidises several direct-acting oral anticoagulants only under defined clinical criteria, influencing how clinicians move between warfarin and the newer agents after discharge. Differences in body mass distribution, regional referral pathways, and the diversity of patients referred from rural and remote communities also mean that a single regimen rarely applies uniformly across the country.

Contemporary guidance from the Cardiac Society of Australia and New Zealand, working alongside international bodies, continues to favour a rate-first approach in haemodynamically stable patients, with rhythm control reserved for symptomatic, refractory, or haemodynamically compromising episodes. What separates the postoperative setting from the outpatient clinic is the compressed time frame, the physiological fragility of the patient, and the layered polypharmacy. The following sections walk through the pharmacological options, the supporting evidence, and the practical considerations that Australian teams weigh when individualising therapy in adults recovering from cardiothoracic operations.

For multidisciplinary teams, the article also serves as a refresher on the rhythm and rate control decisions that frequently fall to registrars overnight, when senior review may take time to arrange. Familiarity with local protocols reduces variability and shortens the time to appropriate therapy.

Incidence and Risk Stratification in the Surgical Setting

Several patient- and procedure-specific factors consistently predict the onset of atrial fibrillation after cardiothoracic operations. Advanced age, particularly beyond 70 years, prolonged aortic cross-clamp time, prior history of arrhythmia, valvular pathology (especially mitral), reduced left ventricular ejection fraction, and chronic obstructive pulmonary disease all contribute to an elevated risk. Intraoperative handling of the atria, the type of cardioplegia, and the extent of pericardial disruption compound these vulnerabilities. Australian surgeons have documented comparable risk profiles in local cohorts, and the CSANZ-led registries reaffirm that patient-level variables dominate over centre-level variations.

Risk stratification is not an abstract exercise; it informs preoperative counselling, the intensity of postoperative telemetry, and the threshold for empirical beta-blockade continuation. Many Australasian units restart or initiate metoprolol on the first postoperative morning in patients without contraindications, leveraging the drug's familiarity, predictable pharmacokinetics, and ease of titration. Where bradycardia, hypotension, or low cardiac output precludes beta-blockade, clinicians document the contraindication explicitly and identify alternative rate-limiting agents. This documentation matters for handover between intensive care unit registrars and the cardiology consult team, which often assumes arrhythmia management after the first 24 hours.

Rate Control Strategies in the Early Postoperative Period

Beta-adrenoceptor blockers remain the cornerstone of rate control for most patients in the first 48 to 72 hours. Metoprolol given intravenously in divided doses, or as a continuous infusion of esmolol in tenuous cases, allows rapid titration. Esmolol's short half-life makes it useful when haemodynamic status is uncertain, although Australian practice tends to prefer metoprolol as the default once blood pressure and perfusion are stable. Sotalol occupies a narrower niche, combining beta-blockade with class III antiarrhythmic activity but carrying the additional burden of QT prolongation, which limits its use in patients receiving other agents that affect repolarisation.

Non-dihydropyridine calcium channel blockers such as diltiazem and verapamil offer an effective alternative when beta-blockers are contraindicated, yet their negative inotropic effect requires caution in the early postoperative phase. Intravenous diltiazem can produce reasonable rate reduction but should be paired with invasive monitoring in patients with borderline ventricular function. Digoxin retains a role in select cases, particularly when rate control is needed in a patient already on inotropes, or when renal function favours its use. Its slow onset, however, makes it less attractive for acute management where rapid response is required.

Magnesium sulphate, while not a primary rate-control agent, deserves emphasis given consistent evidence from Australian and international studies that intravenous supplementation reduces the incidence of postoperative atrial fibrillation, particularly in patients with low baseline serum levels. Many units, including those at the Austin Hospital in Melbourne and Nepean Hospital in western Sydney, incorporate empirical magnesium into their fast-track recovery protocols, complemented by potassium targets above 4.5 mmol/L.

Rhythm Control with Antiarrhythmic Agents

When rhythm control becomes necessary, amiodarone is the dominant agent across adult cardiac surgical populations in Australia. Its multichannel blocking effects, modest negative inotropy, and availability in both intravenous and oral formulations make it the practical first choice for haemodynamically stable new-onset atrial fibrillation that has not responded to rate control. Loading typically begins with an intravenous bolus followed by a continuous infusion for 24 to 48 hours, with transition to oral maintenance. Hepatic, thyroid, and pulmonary toxicity monitoring forms part of longer-term follow-up, particularly as many patients transition to outpatient management through hospital-based arrhythmia clinics.

Ibutilide, favoured in some North American centres for rapid cardioversion of atrial flutter, holds limited utility in Australian practice owing to its QT-prolonging profile and the additional monitoring infrastructure it requires. Sotalol can be considered where beta-blockade is needed alongside class III activity, but its use is constrained by renal function and concurrent QT-affecting drugs. For patients who cannot tolerate these agents, electrical cardioversion often becomes the safest option, leaving pharmacological therapy as a bridge rather than a long-term solution.

The selection of antiarrhythmic drugs does not occur in isolation. Postoperative patients are typically exposed to ondansetron, fluconazole or similar antifungals, fluoroquinolones, and macrolide antibiotics, all of which can prolong the QT interval. Detailed discussion of QTc monitoring considerations reminds clinicians that the arrhythmia being treated and the therapies being employed both contribute to repolarisation abnormalities. Frequent 12-lead or continuous telemetry review, paired with daily electrolyte adjustment, is essential.

Anticoagulation Decisions in the Recovery Phase

Stroke prevention is rarely the first consideration during the chaotic first 24 hours, yet decisions made in this window set the trajectory for the weeks that follow. Postoperative bleeding risk must be balanced against thromboembolic concern, particularly when atrial fibrillation persists beyond 48 hours. Warfarin has historically been the default anticoagulant in Australia, valued for reversibility and clinical familiarity, but its delayed onset, narrow therapeutic window, and need for INR monitoring create friction in the early recovery period.

Direct oral anticoagulants have reshaped the landscape. Apixaban, rivaroxaban, and dabigatran are listed on the Pharmaceutical Benefits Scheme under specific clinical criteria, which most often apply to non-valvular atrial fibrillation. Local prescribing habits vary: large academic centres may lean towards apixaban for its predictable dosing and favourable bleeding profile, while smaller regional hospitals often default to warfarin in patients returning to remote communities where INR monitoring is feasible through local pathology services. The recent Australian guideline updates emphasise shared decision-making, particularly where adherence, cost, and follow-up access are relevant.

For patients with mechanical mitral valves or moderate-to-severe mitral stenosis, the calculus is different. Warfarin remains the evidence-based standard, and clinicians should document the specific indication clearly. Timing of anticoagulant initiation must account for chest drain output, haemoglobin trend, and procedural bleeding risk — typically a pause of 24 to 48 hours after drain removal in uncomplicated cases. Bridging therapy with unfractionated heparin can be considered in higher thromboembolic risk scenarios, although its role has narrowed as evidence has accumulated.

Local Protocol Development and Monitoring Considerations

Unit-level consistency reduces prescribing errors and streamlines handover. A growing number of Australian hospitals now publish internal atrial fibrillation pathways that combine rate and rhythm control algorithms, electrolyte targets, anticoagulation thresholds, and escalation triggers for the cardiology and cardiothoracic teams. These protocols frequently link to electronic prescribing systems that flag QT-prolonging combinations, renal dose adjustments, and interactions with amiodarone. Embedding pharmacists into the postoperative round has become a recognised quality improvement strategy, with published work from Australian teaching hospitals showing measurable reductions in inappropriate prescribing.

Monitoring extends beyond the index admission. Patients discharged in stable sinus rhythm without prolonged episodes may not require ongoing anticoagulation once postoperative inflammation settles, although decisions should follow current guideline-derived scores. Those with persistent atrial fibrillation at six weeks are usually transitioned to long-term anticoagulation, cardiology follow-up, and structured review of antiarrhythmic therapy. Education on pulse checking, when to present for review, and medication adherence forms part of discharge planning that nurses and pharmacists deliver across most tertiary centres.

Continued engagement with the published literature remains the foundation of safe pharmacological practice in this evolving field. For clinicians interested in the broader conversation around postoperative arrhythmia care, the Journal of Arrhythmia continues to publish themed collections that include critical care monitoring, pharmacology updates, and review articles from the regional research community. Reviewing the recent literature alongside local audit data — particularly around QTc stewardship, anticoagulation access, and equity of follow-up in regional areas — keeps practice aligned with the best available evidence and supports consistent care across Australian cardiac surgical services.